Chiusura precedente | 6,43 |
Aperto | 6,59 |
Denaro | 6,35 x 400 |
Lettera | 6,43 x 400 |
Min-Max giorno | 6,02 - 6,60 |
Intervallo di 52 settimane | 0,66 - 11,40 |
Volume | |
Media Volume | 5.298.636 |
Capitalizzazione | 187,531M |
Beta (5 anni mensile) | 0,92 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,31 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 11,00 |
One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancerTwo preclinical posters characterizing new developments from the enLIGHTEN™ Discovery Platform NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral
Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival curveNegative or low PD-L1 status appears to be associated with long survival in CAN-2409 treated patientsBiomarker data suggests association between immune cell activation and survivalTopline overall survival data expected in Q2 2024 NEEDHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company foc
NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City. Format: Corporate PresentationD